摘要
目的观察斑蝥酸钠维生素B_(6)联合化疗药物胸腔内热灌注治疗肺癌合并恶性胸腔积液的疗效和安全性。方法选取2018—2022年扬中市人民医院收治的肺癌合并恶性胸腔积液患者130例,按照随机抽签法分为A组与B组,各65例。所有患者将胸腔积液完全排出后,A组经导管注入注射用顺铂、地塞米松磷酸钠注射液、注射用人白介素-2胸腔内热灌注,B组在A组基础上加用斑蝥酸钠维生素B_(6)注射液胸腔内热灌注。比较2组临床疗效,KPS评分改善分级,治疗前后肿瘤标志物[癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)和神经元特异性烯醇化酶(NSE)],不良反应。结果B组客观缓解率高于A组(82.67%vs.50.67%,χ^(2)=17.280,P<0.001)。B组KPS评分改善分级优于A组(u=2.053,P=0.040)。治疗后,2组血清CEA、CYFRA21-1、NSE水平低于治疗前,且B组低于A组(P<0.01)。B组与A组不良反应总发生率比较,差异无统计学意义(34.67%vs.29.33%,χ^(2)=0.490,P=0.484)。结论斑蝥酸钠维生素B_(6)联合化疗药物胸腔内热灌注治疗肺癌合并恶性胸腔积液可提高疗效、改善患者功能状态,抑制肿瘤标志物表达,延缓病情进展,且未提高不良反应发生率。
Objective To observe the efficacy and safety of disdium cantharidinate and vitamin B_(6)combined with chemotherapy drugs intrapleural thermal perfusion in the treatment of lung cancer complicated with malignant pleural effusion.Methods One hundred and thirty cases of lung cancer patients complicated with malignant pleural effusion admitted to Yangzhong People′s Hospital from 2018 to 2022 year were selected and divided into the A group and the B group according to the method of random draw,with 65 patients in each group.After all patients had completely discharged the pleural effusion,the A group were injected with cisplatin for injection,dexamethasone sodium phosphate injection,and recombinant human interleukin-2 for injection intrapleural hyperthermia via catheterization,the B group received intrapleural thermal perfusion of disdium cantharidinate and vitamin B_(6)injection on the basis of the A group.Clinical efficacy,KPS score improvement grade,tumor markers(CEA,CYFRA21-1 and NSE)before and after treatment,adverse reactions were compared between the two groups.Results The objective remission rate of the B group was higher than that of the A group(82.67%vs.50.67%,χ^(2)=17.280,P<0.001).The KPS score improvement grade of the B group was better than that of the A group(u=2.053,P=0.040).After treatment,the serum levels of CEA,CYFRA21-1 and NSE in the two groups were lower than those before treatment,and the B group were lower than those in the A group(P<0.01).There was no statistically significant difference in the total incidence of adverse reactions between the B group and the A group(34.67%vs.29.33%,χ2=0.490,P=0.484).Conclusion Disdium cantharidinate and vitamin B_(6)combined with chemotherapy drugs can improve the curative effect and functional status of lung cancer patients complicated with malignant pleural effusion,which can inhibit the expression of tumor markers,then delay the progress of disease,and without increasing the incidence of adverse reactions.
作者
周平
吴华
陆斌
ZHOU Ping;WU Hua;LU Bin(Clinical Pharmacy Department,Yangzhong People′s Hospital,Jiangsu Province,Yangzhong 212200,China;不详)
出处
《临床合理用药杂志》
2024年第3期22-25,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
肺癌
恶性胸腔积液
斑蝥酸钠维生素B_(6)
顺铂
热灌注
治疗结果
肿瘤标志物
Lung cancer
Malignant pleural effusion
Disdium cantharidinate and vitamin B_(6)
Cisplatin
Thermal perfusion
Treatment outcome
Tumor markers
